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Synthetic cathinones are the second most commonly seized new psychoactive 26 
substance family in Europe. These compounds have been related to several intoxication 27 
cases, including fatalities. Although the pharmacological effects, metabolism and 28 
pharmacokinetics of cathinones have been studied, there is little information about the 29 
permeability of these compounds through the blood-brain barrier (BBB). This is an 30 
important parameter to understand the behaviour and potency of cathinones. In this work, 31 
13 selected cathinones have been analysed in telencephalon tissue from Sprague-Dawley 32 
rats intraperitoneally dosed at 3 mg/kg. Our results revealed a direct relationship between 33 
compound polarity and BBB permeability, with higher permeability for the more polar 34 
cathinones. The chemical moieties present in the cathinone had an important impact on 35 
the BBB permeability, with lengthening of the α-alkyl chain or functionalization of the 36 
aromatic ring with alkyl moieties resulting in lower concentration in telencephalon tissue. 37 
Our data suggest that transport of cathinones is a carrier-mediated process, similar to 38 
cocaine transport across the BBB.  39 
 40 
Keywords Blood-brain barrier, new psychoactive substances, synthetic cathinones, 41 
pharmacokinetics, pharmacology, toxicological analysis. 42 
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Introduction  44 
The consumption of synthetic cathinones represents an important public health 45 
problem, according to the most recent report from the United Nations Office on Drugs 46 
and Crime 1, which illustrates that this new psychoactive substance (NPS) family is one 47 
of the most commonly seized worldwide, together with synthetic cannabinoids 1. Most of 48 
the cathinone seizures are powder, together with pills and similar products. These 49 
compounds have also been found as adulterants in “classical” illegal drugs such as 50 
cocaine, illustrating that their prevalence of consumption could be underestimated 2,3. In 51 
addition to the data obtained by seizure analysis, the public health problem related to 52 
cathinones is also illustrated by numerous intoxication cases related to these substances, 53 
and even some fatalities 4–6. The synthetic cathinones prevalence can also be illustrated 54 
by analytical data obtained from wastewater analysis, illustrating that these compounds 55 
are being consumed worldwide 7,8. 56 
It is almost impossible to ban all the cathinone derivatives existing nowadays due to 57 
the continuous change in structure of new compounds appearing on the market. Besides, 58 
new compounds that could replace banned ones surface in mere weeks, in a similar way 59 
to what occurs with synthetic cannabinoids 9. To face this public health problem, the 60 
scientific community must be able to provide information about novel compounds, their 61 
chemical, pharmacological and toxicological properties. Thus, a notable number of 62 
papers have been published, as illustrated by the reviews available in literature about the 63 
metabolism of these substances 10–12, the associated pharmacological behavior 13,14, 64 
toxicology 5,15, and even their neurotoxicity 16. 65 
An important pharmacological issue to highlight is how cathinones affect endogenous 66 
compounds, producing a psychoactive effect. Several studies have demonstrated that 67 
cathinones act as non-selective monoamine uptake inhibitors, increasing the levels of 68 
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dopamine and serotonin 17,18, producing effects similar to cocaine 19,20. Thus, the potency 69 
of cathinones and other NPS may be studied using in vitro approaches 21–23, in a similar 70 
way to synthetic cannabinoids 24. Although in vitro studies provide valuable information 71 
about the intrinsic potency of a compound, the in vivo effect must be determined by the 72 
extent to which a compound reaches its site of action. One of the key barriers in this 73 
context is the blood-brain barrier (BBB), modulating the exchange of compounds 74 
between the brain and the blood 25. The BBB is a complex system that presents different 75 
“entry routes” that can be used by drugs or hormones 25, such as passive diffusion (usually 76 
used by non-polar compounds such as steroids) and carrier-mediated influx 25 (used by 77 
some psychoactive substances such as cocaine 26), whereby a specific transporter helps 78 
the compound to cross the BBB and reach the brain. To complement the in vitro data and 79 
better understand the pharmacokinetics (and in vivo potency) of cathinones, it is therefore 80 
essential to generate accurate data on the BBB permeability of these compounds 26.  81 
This work is the first to quantify an extensive series of cathinones in brain samples 82 
from rats intraperitoneally injected with these compounds, with the objective of relating 83 
the permeability through the BBB with their structure. To this aim, we have developed 84 
and validated 27–30 advanced analytical methodology based on ultra-high performance 85 
liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) for the 86 
determination of 13 cathinones (Figure 1) in Sprague-Dawley rats’ telencephalon tissue. 87 
UHPLC coupled to mass spectrometry (MS) plays an essential role in cathinone analysis, 88 
using both high-resolution MS (HRMS) and low-resolution MS/MS. Thus, most studies 89 
about the identification of novel cathinones 31–33 and the elucidation of their metabolites 90 
34–36 have utilized UHPLC-HRMS, taking profit of the full-spectrum acquisition and high 91 
mass accuracy provided by this technique. UHPLC-MS/MS is the preferred technique for 92 
the accurate and sensitive determination of a predetermined list of compounds, and has 93 
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often been used for studying the pharmacokinetics and pharmacodynamics of cathinones 94 
20,37–40.  95 
As shown in Figure 1, taking pentedrone as a template, the cathinones investigated in 96 
this study differ in the amine functionalization, aromatic ring substitutions and/or length 97 
of the alkyl chain of the alpha carbon atom. The studied compounds were thoroughly 98 
selected in order to cover most of the possible combinations of moiety changes usually 99 
appearing in cathinones. Using a human in vitro BBB permeability model, Simmler et al. 100 
readily assessed the transendothelial transport of a series of cathinones 17, whereas the 101 
permeability of three cathinones with different alkyl chain length (methylone, butylone 102 
and pentylone) was evaluated by Grecco et al. using Sprague-Dawley rats 41. Our work 103 
further elaborates on this by testing in vivo an extensive set of well-chosen cathinones 104 
with different changes in the moieties of the molecule.  105 
 106 
Materials and methods 107 
Reagents and chemicals  108 
Research chemicals containing cathinones were provided by Energy Control (ABD 109 
Foundation, Barcelona, Spain). All the compounds were characterized and purity-110 
tested by UHPLC-HRMS and nuclear magnetic resonance, following the same 111 
procedures already reported in literature 42,43. Cathinone stock solutions were prepared 112 
at approximately 1 mg/mL in methanol (0.01 mg accuracy). HPLC-grade water was 113 
obtained by purifying demineralized water using a Milli-Q system from Millipore 114 
(Bedford, MA, USA). HPLC-grade methanol, HPLC-grade acetonitrile, HPLC-grade 115 
ethanol, formic acid and acetone were purchased from Scharlau (Scharlab, Barcelona, 116 
Spain). Physiological saline solution was purchased from Laboratorios ERN 117 
(Barcelona, Spain). 118 
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Animal testing 119 
For animal experiments, dose and brain dissection time were selected based on the 120 
information available in literature. In this work, a realistic 3 mg/kg dose 40 was preferred 121 
over the very large doses (around 20 mg/kg) used in other pharmacokinetic studies 39,41. 122 
This is relevant because extremely high doses could affect the metabolome, metabolic 123 
routes or active transport - among other parameters - that could be involved in the 124 
pharmacology and pharmacokinetics of these compounds. It should be noted that, 125 
depending on the compound, the doses reported by users are vastly different. For 126 
example, in the case of pentedrone, the compound used as reference in this work, 30 to 127 
60 mg has been described as a typical dose when using intravenous route (roughly 0.5 to 128 
1.0 mg/kg) 44. However, for the aim of this work, it seemed reasonable to use similar 129 
doses for all the tested compounds, in order to facilitate the interpretation of the results 130 
and avoid the influence of different cathinone concentrations on the data obtained. 131 
Peters and colleagues 40 quantified three cathinones in rat brains by LC-MS/MS, dosing 132 
the rats at 3 mg/kg for methylone and mephedrone, and at 1 mg/kg for MDPV. 133 
Pharmacokinetic data obtained revealed that the highest concentration was achieved 20 134 
min after administration. Also another study 45, studying the variation of monoamine 135 
transporters in brain tissue from rats injected at 1, 3 and 10 mg/kg, reported the highest 136 
concentration in brain tissue 20 min after injection. Based on these studies, 3 mg/kg was 137 
selected as the dosage to be administered to the rats for all the compounds, and the brain 138 
was dissected 20 min post-injection. 139 
Thus, thirty female Sprague-Dawley rats (8 weeks of age), weighing between 280 140 
and 320 g, were purchased from Janvier Labs (Le Genest-Saint-Isle, France). 141 
Animals were housed in groups of 3 animals in polypropylene plastic cages under 142 
controlled temperature (24 ±2 ºC) and lighting conditions (12h:12h; lights ON at 8 143 
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am), with ad libitum access to food and water. Before drug administration, animals 144 
were handled and habituated to the experimental room for one week. Experiments 145 
were conducted in accordance with the standard ethical guidelines (European 146 
Communities Directive 86/60-EEC) and approved by the Valencian Region 147 
government ethical committee (Generalitat Valenciana, Direcció General 148 
d’Agricultura, Ganaderia i Pesca, ref. 2019/VSC/PEA/0048). 149 
Two rats were dosed per compound and the brains were pooled in order to avoid 150 
possible animal differences. In total, twenty-six rats received intraperitoneal injections 151 
of the 13 different cathinones at a dose of 3 mg/kg in 300 µL of physiological saline 152 
solution containing 5% ethanol – the latter for increasing the solubility of the 153 
synthetic cathinones. Four additional animals were injected with the same volume of 154 
the vehicle and used to obtain blank brain tissue samples, to be used to prepare quality 155 
control samples (QCs) and matrix-matched calibration curves. After 20 min, rats were 156 
anesthetized with CO2 and decapitated immediately. The brain was dissected 157 
(avoiding blood that could contaminate it), and the telencephalon (both cerebral 158 
hemispheres) was isolated, quickly frozen in liquid nitrogen and stored at -23 ºC until 159 
analysis.  160 
Sample treatment 161 
Brain tissue samples were homogenized and crushed with dry ice (Praxair, Valencia, 162 
Spain) using an electric grinder, followed by a -23 ºC overnight storage for CO2 163 
evaporation. After that, approximately 250 mg were accurately weighted (± 0.1 mg) in 164 
1.5 mL polypropylene tubes, and 750 µL of acetonitrile containing 1% of formic acid 165 
were added. Samples were extracted for 30 min under agitation using a vortex (Velp 166 
Scientifica, Usmate Velate, Italy) at 1200 rpm. After keeping extracts for 30 min at -23 167 
ºC, samples were centrifuged at 12000 rpm for 10 min. Finally, the supernatant was 168 
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diluted with ultrapure water for UHPLC-MS/MS analysis: in the case of samples used for 169 
method validation, the supernatant was 10-fold diluted, whereas for the brain samples 170 
obtained after administration of cathinones, supernatant was 1000-fold diluted. 171 
The sample treatment procedure was adapted from literature 19, with the only difference 172 
being the homogenization procedure. In the present study, homogenization was 173 
performed using an electric grinder and dry ice, followed by extraction with acetonitrile 174 
and 1% formic acid, a freezing step as clean-up and dilution of the supernatant with 175 
HPLC-grade water. Sample weight, extraction volumes and dilutions were designed 176 
according to information available in literature 40, with some modifications to improve 177 
method sensitivity. For a detailed description on analytical methodology validation and 178 
the results obtained, see Supporting Information. 179 
 180 
Instrumentation 181 
Samples were analyzed using an Acquity UPLCTM H-Class liquid chromatography 182 
system (Waters Corp, Mildford, MA, USA) coupled to a Xevo TQ-S mass spectrometer 183 
(Waters Corp, Manchester, UK) equipped with a triple quadrupole mass analyzer, using 184 
a Z-Spray electrospray interface (ESI). Further information about the UHPLC-MS/MS 185 




Cathinone concentrations found in brain displayed wide differences, from 762 ng/g 190 
brain tissue for N,N-dimethylpentylone to 10596 ng/g for N-ethyl-pentylone, the 191 
concentrations for most of the remaining compounds ranging between 1000 and 4000 192 
ng/g. In all cases, the concentrations were well above the analytical performance, in terms 193 
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of sensitivity and limits of quantification of our methodology. In addition, reliability of 194 
the analytical methodology was supported by analysis of quality control (QC) samples in 195 
duplicate, spiked at 1 and 10 ng/g, included in the sample batch. Recoveries between 70 196 
and 120% were obtained, confirming the correct quantification of the cathinones in 197 
telencephalon tissue. 198 
The concentrations found in telencephalon samples for all the compounds are shown 199 
in Tables 1-3. The differences observed in the cathinone levels suggest that the BBB 200 
permeability of these compounds is structure-dependent, being associated with their 201 
polarity, as discussed further. 202 
 203 
Discussion 204 
Cathinone penetration through the blood-brain barrier 205 
The main objective of our study was to evaluate the relationship between the structure 206 
of cathinones and their BBB permeability, in order to get better acquainted with the 207 
pharmacological behaviour of these substances.  208 
Pronounced concentration differences were observed in the telencephalon for different 209 
cathinones, ranging from 762 ng/g (N,N-dimethylpentylone) to 10596 ng/g (N-ethyl-210 
pentylone). This difference is surprising given the very high structural similarity of these 211 
two compounds, which only differ in the amine functionalization (dimethyl vs. ethyl).  212 
Table 1 shows the concentrations found in telencephalon tissue for cathinones that 213 
differ by the functionalization of the amine moiety (N). In the two groups (those without 214 
aromatic ring substitution and those with a 3,4-methylenedioxy substituent), cathinones 215 
with an N-methyl (pentedrone and pentylone) moiety were found at a higher 216 
concentration than those with a pyrrolidine ring (α-PVP and MDPV). Regarding 217 
compounds with an N-ethyl group, N-ethyl-pentedrone had lower permeability than the 218 
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N-methyl analogue whereas N-ethyl-pentylone had a higher permeability than the N-219 
methyl analogue. It is also remarkable that the cathinone with a N,N-dimethyl group (N,N-220 
dimethylpentylone) seemed to have the lowest permeability of the BBB. 221 
N-ethyl-pentylone was, by far, the cathinone with the highest concentration in 222 
telencephalon tissue. Also known as ephylone or bk-EBDP, this substance is a recently 223 
reported cathinone that has been involved in numerous recent intoxication cases 46,47 224 
including 151 deaths between 2014 and 2018 48, which raises high concerns regarding the 225 
toxicity of this compound. The high N-ethyl-pentylone concentration found in 226 
telencephalon tissue is in line with a recent study about the pharmacokinetic behavior of 227 
this cathinone, which also suggested a high BBB permeability 39, which could explain its 228 
elevated toxicity. 229 
Another common modification seen in cathinone analogs is altering the length of the 230 
alkyl chain. In this study, we evaluated three pairs of cathinones that only differed from 231 
each other in the length of the alkyl chain. (Table 2): buphedrone and pentedrone, N-232 
ethyl-pentedrone and N-ethyl-hexedrone, and butylone and pentylone. In all three cases, 233 
lengthening the alkyl chain led to a reduction of the BBB permeability, as shown in Table 234 
2. These results are in concordance with data reported in a similar study 41, where the 235 
permeability of methylone, butylone and pentylone through the BBB was evaluated. The 236 
reported concentrations in cerebrospinal fluid were around 13 mg/L for butylone and 7 237 
mg/L for pentylone after dosing Sprague-Dawley rats at 20 mg/kg. These results are 238 
coherent with those of the present study, where around 6,000 and 3,700 ng/g butylone 239 
and pentylone, respectively, were found in telencephalon for rats dosed at 3 mg/kg. Based 240 
on these data, the increment of the non-polarity of the cathinones due to the increase of 241 
the alkyl chains produces a reduction of the BBB permeability. Strangely, the most potent 242 
cathinone analogs in terms of dose reported by consumers are those that have a three-243 
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carbon alkyl chain: MDPV, pentylone, α-PVP, pentedrone, etc., with the dose being 244 
higher if the length is shortened or increased further in most cases 49. This could indicate 245 
that the mechanisms of toxicity of these compounds are not directly linked to their BBB 246 
permeability. As can be seen in the case studies for bk-EBDP intoxications, users 247 
frequently report a long duration of action for this compound, which is not so common 248 
for other cathinones. Perhaps the duration of effects indicates that bk-EBDP lingers in the 249 
body for an unusually long amount of time, and some of the toxicity may stem from this 250 
phenomenon. 251 
The last typical change in the cathinone structure is functionalization of the aromatic 252 
ring. As can be observed in Table 3, the functionalizations studied were the addition of a 253 
3,4-methylenedioxy moiety, a methyl group, a 3,4-dimethoxy group, and the addition of 254 
an halogen atom (in this case, a fluorine). Three of the four cathinone couples 255 
with/without a 3,4-methylenedioxy moiety (buphedrone and butylone, pentedrone and 256 
pentylone, and α-PVP and MDPV) presented a reduction of the permeability through the 257 
BBB when this moiety was added to the molecule (Table 3), and it could also be related 258 
to the increment of the non-polarity of the compound by this modification. The 259 
remarkably low brain tissue concentration (860 ng/g) for MDPV is in line with previously 260 
reported concentrations for MDPV in rat brain, quantified around 260 ng/g at 30 min 261 
when dosing a rat at 1 mg/kg 38. Only for the couple N-ethyl-pentedrone and N-ethyl-262 
pentylone, the cathinone with the 3,4-methylenedioxy moiety presented a higher 263 
concentration in telencephalon tissue. Similar to the results obtained when analyzing the 264 
N-functionalization (Table 1), N-ethyl-pentylone produced an unexpected result when 265 
compared to the other cathinones. The higher telencephalon concentration of 4-266 
fluoropentedrone, when compared with pentedrone, suggests that the presence of a 267 
halogen atom may increase BBB permeability, potentially due to an increment of the 268 
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compound’s polarity. The reason for the increment of the permeability observed when 269 
adding a methyl group (N-ethyl-pentedrone vs N-ethyl-4-methylpentedrone) or a 3,4-270 
dimethoxy group (α-PVP vs 3,4-dimethoxy-α-PVP) is unclear. It is possible that the 271 
presence of these terminal methyl groups allows for easier passing through the BBB. In 272 
order to confirm this, more cathinones with these aromatic ring changes should be 273 
evaluated. 274 
The concentration differences discussed above, when changing the N-275 
functionalization, alkyl chain length and aromatic ring substitution, point at a positive 276 
correlation between polarity and BBB permeability, as also suggested by others 41. 277 
However, based on an in vitro model using TY09 conditionally immortalized human 278 
brain capillary endothelial cells, Simmler and colleagues suggested the opposite: these 279 
authors reported that a decrease in polarity of cathinones produces an increment of the 280 
permeability of the BBB, with non-polar cathinones presenting a particularly high 281 
transendothelial permeability 17. Although these in vitro data apparently contradict our 282 
findings and those of the previous literature 38,41, the use of live animals instead of a cell 283 
culture is a closer representation of the real pharmacokinetic behavior of these compounds 284 
in a process as complex as BBB permeability. 285 
In fact, the BBB is composed not just of endothelial cells, but also includes associated 286 
cell elements such as astrocyte endfeet, pericytes and microglia. There are several 287 
important routes of transport across the BBB 25, passive diffusion and the carrier-288 
mediated influx being the most common ones related to psychoactive substances. The 289 
coexistence of both influx processes for cocaine through the BBB has been reported in 290 
literature using an in vivo model with Swiss mice; here, the carrier mediated influx rate 291 
was 3.4 times greater than its passive diffusion rate 26. The same publication indicates that 292 
MDPV is also a substrate for the cocaine transporter. Based on this evidence and in line 293 
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with the data presented in this work as well as in literature 41, it can be deduced that the 294 
penetration of cathinones through the BBB is a carrier-mediated process. An exhaustive 295 
study about the solute carrier transporters involved in cathinone transport should be 296 
performed in order to confirm this hypothesis. 297 
In addition to compound polarity and moieties present in the distinct structures, 298 
different physicochemical properties of the compounds such as logP and logD, 299 
topological polar surface area, number of rotatable bonds, fraction of sp3 carbons, heavy 300 
atom count, among other parameters, can be also be related to BBB permeability. For the 301 
compounds studied in this work, topological polar surface area values (obtained from 302 
PubChem) were evaluated for 11 compounds. No relationship between this parameter and 303 
BBB permeability was found. No additional parameters were found in compound 304 
databases, consequently those should be determined experimentally or theoretically to 305 
evaluate their contribution to BBB permeability. 306 
In summary, the relationship between cathinone structure and their ability to cross the 307 
blood-brain barrier was studied in this work. To this aim, telencephalon tissues from 308 
Sprague-Dawley rats dosed at 3 mg/kg with 13 different cathinones were analyzed by a 309 
validated UHPLC-MS/MS procedure. The results obtained showed that permeability of 310 
cathinones is related to their polarity, with better crossing of the BBB with increasing 311 
polarity. These findings are in accordance with previously published data using rats 41 but 312 
differ from those obtained using in vitro experiments 17, demonstrating the importance of 313 
not solely relying on in vitro data. Less polar N functionalizations, such as the presence 314 
of a pyrrolidine ring, reduced the cathinone transport through the BBB. In a similar way, 315 
cathinones with longer alkyl chain were less able to cross the BBB. Non-polar aromatic 316 
ring substitutions such as 3,4-methylenedioxy reduced BBB permeability, while the 317 
presence of a fluorine atom increased BBB transport. All this data, together with 318 
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information available in literature from similar studies 41 and the BBB transport 26 suggest 319 
that cathinones cross the BBB through a carrier-mediated process. Additionally, this 320 
study shows that studying the pharmacology and pharmacokinetics of cathinones, and 321 
NPS as a whole, is crucial for a better understanding of the in vivo potency of these 322 
compounds, complementing other studies such as dopamine and serotonin uptake 323 
inhibition. Our future work will be focused on the study of additional cathinones that will 324 
appear on the continuously evolving NPS market, in order to support the role of carrier-325 
mediated processes in the BBB passage of cathinones. 326 
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Table 1. Concentration levels found in rat telencephalon tissue for cathinones differing 531 
on the amine (N) functionalization (rats dosed at 3 mg/kg). 532 
 Change in the N functionalization 
Compound 





Pentedrone 3,718 1.03 
 
α-PVP 3,054 0.84 
 
N-Ethyl-pentedrone 1,432 0.40 
 
Pentylone 3,113 0.86 
 
MDPV 863 0.24 
 
N-Ethyl-pentylone 10,596 2.94  
N,N-Dimethylpentylone 762 0.21 
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Table 2. Concentration levels found in rat telencephalon tissue for cathinones differing 535 
on the alkyl chain length (rats dosed at 3 mg/kg). 536 
 Alkyl chain length 
Compound 





Buphedrone 6,067 1.69  
Pentedrone 3,718 1.03 
 
N-Ethyl-pentedrone 1,432 0.40 
 
N-Ethyl-hexedrone 1,160 0.32 
 
Butylone 4,659 1.29  
Pentylone 3,113 0.86 
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Table 3. Concentration levels found in rat telencephalon tissue for cathinones differing 539 
on the aromatic ring substitutions (rats dosed at 3 mg/kg). 540 
 Aromatic ring substitution 
Compound 





Buphedrone 6,067 1.69  
Butylone 4,659 1.29 
 
Pentedrone 3,718 1.03 
 
Pentylone 3,113 0.86  
4-Fluoropentedrone 4,806 1.34 
 
N-Ethyl-pentedrone 1,432 0.40 
 
N-Ethyl-pentylone 10,596 2.94 
 
N-Ethyl-4-methylpentedrone 2,541 0.71 
 
α-PVP 3,054 0.85 
 
MDPV 863 0.24  
3,4-dimethoxy-α-PVP 2,083 0.58 
 
 541 
